Progyny, Inc. (PGNY)
| Market Cap | 2.00B +6.5% |
| Revenue (ttm) | 1.29B +6.6% |
| Net Income | 67.69M +28.9% |
| EPS | 0.76 +34.9% |
| Shares Out | 78.33M |
| PE Ratio | 33.34 |
| Forward PE | 12.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 953,836 |
| Open | 25.08 |
| Previous Close | 24.99 |
| Day's Range | 25.08 - 25.99 |
| 52-Week Range | 16.10 - 28.75 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 29.73 (+16.68%) |
| Earnings Date | May 7, 2026 |
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management s... [Read more]
Financial Performance
In 2025, Progyny's revenue was $1.29 billion, an increase of 10.40% compared to the previous year's $1.17 billion. Earnings were $58.52 million, an increase of 7.70%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PGNY stock is "Strong Buy." The 12-month stock price target is $29.73, which is an increase of 16.68% from the latest price.
News
Progyny price target raised to $31 from $29 at BofA
BofA raised the firm’s price target on Progyny (PGNY) to $31 from $29 and keeps a Buy rating on the shares. Fertility prescription trends and Google search trends suggest Q2…
New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to redu...
Progyny announces $200M share repurchase program
Progyny (PGNY) announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through…
Progyny, Inc. Announces Share Repurchase Program
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a sha...
Progyny Transcript: AGM 2026
Record financial results and strong client retention highlighted, with all shareholder proposals approved. Strategic investments in technology and product enhancements position the company for continued growth in 2026.
Progyny upgraded to Buy from Hold at Canaccord
Canaccord upgraded Progyny (PGNY) to Buy from Hold with a price target of $30, up from $19. The company’s “more conservative guidance philosophy” over the last several quarters has reestablished…
Progyny price target raised to $27 from $23 at Barclays
Barclays raised the firm’s price target on Progyny (PGNY) to $27 from $23 and keeps an Overweight rating on the shares post the earnings report. The company benefitted from better…
Progyny price target raised to $27 from $23 at Barclays
Barclays raised the firm’s price target on Progyny (PGNY) to $27 from $23 and keeps an Overweight rating on the shares.
KeyBanc sees modest Progyny TAM impact from DOL fertility carve-out
KeyBanc notes that the DOL has announced a proposed rule that would allow fertility treatments to be treated as a new category of “excepted benefits.” Excepted benefits sit outside the…
Progyny Transcript: Bank of America Global Healthcare Conference 2026
Strong pipeline growth, high client retention, and expanding partnerships are driving momentum, with new products and digital investments broadening the addressable market. Consistent utilization and a focus on ROI support a positive outlook, while macro trends and employer demand reinforce long-term growth.
Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete A...
Progyny price target raised to $31 from $30 at Citizens
Citizens analyst Constantine Davides raised the firm’s price target on Progyny (PGNY) to $31 from $30 and keeps an Outperform rating on the shares. Progyny’s Q1 revenue and EBITDA beat…
Progyny price target raised to $29 from $27 at BofA
BofA raised the firm’s price target on Progyny (PGNY) to $29 from $27 and keeps a Buy rating on the shares after “a strong quarter” that come against a backdrop…
Progyny reports Q1 adjusted EPS 50c, consensus 44c
Reports Q1 revenue $328.5M, consensus $326.51M. “We’re pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are…
Progyny sees Q2 adjusted EPS 50c-53c, consensus 48c
Sees Q2 revenue $342M-$355M, consensus $347.38M. Sees Q2 adjusted EBITDA $58M-$62M. The company said, “For more than a decade, Progyny (PGNY) has been meeting this need with our solutions, which…
Progyny raises FY26 adjusted EPS view to $1.98-$2.09 from $1.83-$1.95
Consensus $1.89. Narrows FY26 revenue view to $1.37B-$1.41B from $1.36B-$1.41B, consensus $1.38B. Raises FY26 adjusted EBITDA view to $232M-$244M from $224M-$239M. “This quarter’s results reflect topl...
Progyny Earnings Call Transcript: Q1 2026
Record Q1 revenue and profitability exceeded guidance, driven by strong member engagement and margin expansion. Full-year outlook raised, with double-digit growth expected excluding a former client, and robust pipeline and renewal activity supporting future growth.
Progyny Slides: Q1 2026
Progyny has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Progyny Earnings release: Q1 2026
Progyny released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Progyny Quarterly report: Q1 2026
Progyny has published its Q1 2026 quarterly earnings report on May 7, 2026.
Progyny, Inc. Announces First Quarter 2026 Results
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurc...
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period e...
Progyny expands access to fertility, women’s health with Progyny Select
Progyny (PGNY) announces Progyny Select. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model. “Progyny Select is a game-changer...
Progyny Expands Access to Fertility and Women's Health with Industry's First Fully Insured Supplemental Plan
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully i...
Progyny Proxy statement: Proxy filing
Progyny filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.